Results 81 to 90 of about 4,563 (204)
Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists
To date, many known G protein-coupled receptor 55 (GPR55) ligands are those identified among the cannabinoids. In order to further study the function of GPR55, new potent and selective ligands are needed.
Nevalainen, Tapio J. +15 more
core +1 more source
O-1602 Promotes Hepatic Steatosis through GPR55 and PI3 Kinase/Akt/SREBP-1c Signaling in Mice
Non-alcoholic fatty liver disease is recognized as the leading cause of chronic liver disease. Overnutrition and obesity are associated with hepatic steatosis.
Dong-Soon Im +4 more
core +1 more source
Metabolic Syndrome: From Mechanisms to Therapeutic Interventions
A comprehensive overview of molecular mechanisms delves into the potential disease mechanisms of metabolic syndrome, including complex mechanisms such as insulin resistance, chronic low‐grade inflammation, oxidative stress, and epigenetic modifications, and how these mechanisms contribute to the development of metabolic syndrome. Here, the relationship
Mengyao Yan, Qian Xiang
wiley +1 more source
The G protein-coupled receptor 55 (GPR55) is a novel cannabinoid receptor, whose exact role in anxiety remains unknown. The present study was conducted to explore the possible mechanisms by which GPR55 regulates anxiety and to evaluate the effectiveness ...
Qi-xin Shi +7 more
doaj +1 more source
Abstract Cannabinoid products are increasingly used worldwide despite limited psychiatric evidence. This narrative review synthesizes preclinical and clinical evidence on cannabidiol (CBD), cannabinol (CBN), and tetrahydrocannabinol (THC) to clarify their distinct psychiatric profiles and discuss how current evidence may inform ongoing clinical and ...
Yasuhiro Kishi +2 more
wiley +1 more source
Lysophosphatidylinositol-GPR55 signaling in the regulation of metabolism and cardiometabolic disorders [PDF]
G protein coupled receptor 55 (GPR55) was initially identified as the orphan receptor and then suggested to be the atypical "non-CB1/non-CB2" cannabinoid receptor.
Bełtowski, Jerzy; Medical University of Lublin
core +1 more source
Abstract Objective Lennox–Gastaut syndrome (LGS) is a drug‐resistant developmental and epileptic encephalopathy (DEE). Preclinical drug development for LGS is constrained by a lack of syndrome‐relevant animal models. We aimed to evaluate a Gabrb3+/D120N knock‐in (KI) mouse model of LGS by quantifying atypical absence seizures and epileptic spasms and ...
Thomas Harman +5 more
wiley +1 more source
Clinical &Experimental Allergy, Volume 56, Issue 11, Page 1452-1455, November 2026.
Ahmed M. I. Elfiky +7 more
wiley +1 more source
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide and a major contributor to liver‐related morbidity and mortality. Its progressive subtype, metabolic dysfunction–associated steatohepatitis (MASH), is characterized by hepatocellular injury, inflammation,
Zubaier Ahmed +3 more
wiley +1 more source
ABSTRACT Background Skeletal muscle atrophy in amyotrophic lateral sclerosis (ALS) drives loss of muscle strength, function and quality of life in ALS patients. The endocannabinoid system (ECS) regulates muscle homeostasis via regenerative and metabolic processes, and although ECS alterations have been reported in ALS neural tissues, ECS remodelling ...
Sebastiaan Dalle +7 more
wiley +1 more source

